People who have struggled with their weight have found relief with a new drug. But then their weight loss ground to a halt. A ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

MORGANTOWN – WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically significant ... In May 2023, the company reported positive outcomes from its OASIS 1 Phase IIIa trial of oral semaglutide ...

The company added that, as expected from the GLP-1 class ... with Wegovy,” said Martin Holst Lange, NVO’s executive vice president for drug development. The company’s second trial, STEP ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost ... least 25% of their weight in the trial that was dubbed Step Up, it said. Sydbank senior analyst ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's ... the Wegovy brand for obesity. Digging into the data, participants in the 1,407-patient trial started ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...